Recent research have converged on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopamine signaling. While GIP activators are widely employed for addressing type 2 diabetes, their potential consequences on reinforcement circuits, specifically governed by dopaminergic pathw